NO20042586L - Behandlingsfremgangsmate - Google Patents

Behandlingsfremgangsmate

Info

Publication number
NO20042586L
NO20042586L NO20042586A NO20042586A NO20042586L NO 20042586 L NO20042586 L NO 20042586L NO 20042586 A NO20042586 A NO 20042586A NO 20042586 A NO20042586 A NO 20042586A NO 20042586 L NO20042586 L NO 20042586L
Authority
NO
Norway
Prior art keywords
mate
treatment progress
darifenacin
urgency
medicament
Prior art date
Application number
NO20042586A
Other languages
English (en)
Inventor
Enrico Colli
Paul Quinn
Dzelal Serdarevic
Laurenc Howard Skillern
Original Assignee
Novartis Int Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9927643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20042586(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Int Pharm Ltd filed Critical Novartis Int Pharm Ltd
Publication of NO20042586L publication Critical patent/NO20042586L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Processing Of Meat And Fish (AREA)
  • Document Processing Apparatus (AREA)
  • Pyridine Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Inorganic Insulating Materials (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20042586A 2001-12-14 2004-06-18 Behandlingsfremgangsmate NO20042586L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0129962.7A GB0129962D0 (en) 2001-12-14 2001-12-14 Method of treatment
PCT/IB2002/000664 WO2003051354A1 (en) 2001-12-14 2002-03-05 Method of treatment

Publications (1)

Publication Number Publication Date
NO20042586L true NO20042586L (no) 2004-06-18

Family

ID=9927643

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042586A NO20042586L (no) 2001-12-14 2004-06-18 Behandlingsfremgangsmate

Country Status (28)

Country Link
US (3) US20030130338A1 (no)
EP (1) EP1458376B1 (no)
JP (3) JP2005516925A (no)
KR (1) KR100889086B1 (no)
CN (1) CN100488505C (no)
AT (1) ATE341323T1 (no)
AU (1) AU2002236141B2 (no)
BR (1) BR0214925A (no)
CA (1) CA2469702C (no)
CY (1) CY1105814T1 (no)
CZ (1) CZ301283B6 (no)
DE (1) DE60215219T2 (no)
DK (1) DK1458376T3 (no)
ES (1) ES2276910T3 (no)
GB (1) GB0129962D0 (no)
HK (1) HK1073779A1 (no)
HU (1) HU229908B1 (no)
IL (2) IL162391A0 (no)
MX (1) MXPA04005760A (no)
NO (1) NO20042586L (no)
NZ (1) NZ533421A (no)
PL (1) PL206034B1 (no)
PT (1) PT1458376E (no)
RU (1) RU2321398C2 (no)
SI (1) SI1458376T1 (no)
SK (1) SK287510B6 (no)
WO (1) WO2003051354A1 (no)
ZA (1) ZA200404289B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090062326A1 (en) * 2006-03-17 2009-03-05 Spindel Eliot R M3 muscarinic receptor antagonists for treatment of m3 muscarinic receptor-expressing tumors
CN101084891A (zh) * 2007-06-29 2007-12-12 北京本草天源药物研究院 一种用于口服的达非那新或其药用盐的药物制剂
CZ200845A3 (cs) * 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
NZ594311A (en) * 2009-02-04 2013-05-31 Astellas Pharma Inc Pharmaceutical composition comprising tamsulosin and solifenacin for oral administration
CN102048706B (zh) * 2011-01-12 2012-02-22 山东创新药物研发有限公司 一种氢溴酸达非那新缓释片及制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
PT1458376E (pt) 2007-01-31
IL162391A0 (en) 2005-11-20
CN1604777A (zh) 2005-04-06
CN100488505C (zh) 2009-05-20
US20030130338A1 (en) 2003-07-10
CY1105814T1 (el) 2011-02-02
HK1073779A1 (en) 2005-10-21
US20090162433A1 (en) 2009-06-25
DE60215219T2 (de) 2007-10-18
PL369426A1 (en) 2005-04-18
EP1458376B1 (en) 2006-10-04
RU2004121780A (ru) 2005-08-10
ZA200404289B (en) 2005-09-28
MXPA04005760A (es) 2005-03-31
HU229908B1 (hu) 2014-12-29
RU2321398C2 (ru) 2008-04-10
DK1458376T3 (da) 2007-02-12
ATE341323T1 (de) 2006-10-15
CA2469702A1 (en) 2003-06-26
CZ2004719A3 (cs) 2005-01-12
KR20040066892A (ko) 2004-07-27
SK287510B6 (sk) 2010-12-07
DE60215219D1 (de) 2006-11-16
EP1458376A1 (en) 2004-09-22
JP2013199506A (ja) 2013-10-03
NZ533421A (en) 2007-02-23
AU2002236141B2 (en) 2007-02-01
CZ301283B6 (cs) 2009-12-30
HUP0402625A2 (hu) 2005-04-28
US8748476B2 (en) 2014-06-10
IL162391A (en) 2012-04-30
JP2005516925A (ja) 2005-06-09
JP2010024244A (ja) 2010-02-04
SI1458376T1 (sl) 2007-06-30
KR100889086B1 (ko) 2009-03-16
PL206034B1 (pl) 2010-06-30
US20070264333A1 (en) 2007-11-15
ES2276910T3 (es) 2007-07-01
WO2003051354A1 (en) 2003-06-26
GB0129962D0 (en) 2002-02-06
SK2502004A3 (en) 2004-10-05
BR0214925A (pt) 2004-12-21
AU2002236141A1 (en) 2003-06-30
CA2469702C (en) 2010-07-06

Similar Documents

Publication Publication Date Title
MY127290A (en) New use of flibanserin
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
PL1663244T3 (pl) Pochodne pterydyny do leczenia chorób związanych z TNF-alfa
GB0002336D0 (en) Medicaments
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
HK1073779A1 (en) The use of darifenacin and the salt thereof
SE9900070D0 (sv) New use
BG108452A (en) Tablet comprising cetirizine and pseudoephedrine
PT1656131E (pt) Utilização de betaína para tratar claudicação intermitente
EE200100553A (et) Saredutandi ja selle farmatseutiliselt vastuvõetavate soolade kasutamine meeleoluhäirete, kohanemishäirete või segatüüpi ärev-depressiivsete häirete raviks või vältimiseks kasulike ravimite valmistamiseks
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
IL170519A (en) Use of fenofibrate or pharmaceutically acceptable salt thereof, orlistat and pharmaceutically acceptable carrier in the manufacture of medicaments for the treatment of obesity and pharmaceutical compositions containing them
SE9902597D0 (sv) New use
UA83018C2 (uk) Комбінація рофлуміласту і формотеролу для лікування захворювань дихальних шляхів
IL158186A0 (en) Pharmaceutically active compounds and methods of use
MXPA03003980A (es) Uso de melagatran para la elaboracion de un medicamento para el tratamiento de transtornos isquemicos.
UA83017C2 (uk) Комбінація рофлуміласту та r,r-формотеролу для лікування захворювань дихальних шляхів
DK1235573T3 (da) Kombination af riluzol og gabapentin og anvendelse deraf som medikament ved behandling af motorneuronsygdomme
IS7418A (is) Sítalópram til að meðhöndla hækkaðan blóðþrýsting
PL367628A1 (en) Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia
NO20043774L (no) The use of devazenide as analgesic agent
ITRM20020181A0 (it) Medicamento utile per il trattamento della fatica in pazienti affettida sclerosi multipla.
UA43619A (uk) Бетатирон - пролонгований антигіпертензивний засіб нової генерації
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application